{
    "organizations": [],
    "uuid": "79fd6f4447da0d8ae205964309c8aa3f82195301",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pci-biotech-holding-extends-precli/brief-pci-biotech-holding-extends-preclinical-research-collaboration-idUSFWN1PD06A",
    "ord_in_thread": 0,
    "title": "BRIEF-PCI Biotech Holding Extends Preclinical Research Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 18 (Reuters) - PCI BIOTECH HOLDING ASA:\n* EXTENDING PRECLINICAL RESEARCH COLLABORATION WITH UNDISCLOSED TOP-10 PHARMA COMPANY, INITIATED IN SEPTEMBER 2015â€‹\n* WILL EVALUATE DATA GENERATED AND EXPLORE POTENTIAL FOR FURTHER PARTNERSHIP BASED ON OUTCOME\n* - EXTENDED EVALUATION PERIOD SPANS OVER 6 MONTHS, UNTIL THE END OF JUNE 2018, AND MAY BE FURTHER EXTENDED Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-18T15:08:00.000+02:00",
    "crawled": "2018-01-19T12:31:25.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "pci",
        "biotech",
        "holding",
        "asa",
        "extending",
        "preclinical",
        "research",
        "collaboration",
        "undisclosed",
        "pharma",
        "company",
        "initiated",
        "september",
        "evaluate",
        "data",
        "generated",
        "explore",
        "potential",
        "partnership",
        "based",
        "outcome",
        "extended",
        "evaluation",
        "period",
        "span",
        "month",
        "end",
        "june",
        "may",
        "extended",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}